Marshall Wace
ACAD icon

Marshall Wace’s Acadia Pharmaceuticals ACAD Stock Holding History

Marshall Wace’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.7M Buy
1,764,838
+1,688,651
+2,216% +$37.2M 0.04% 418
2026
Q1 		$1.7M Sell
76,187
-417,192
-85% -$9.97M ﹤0.01% 1875
2025
Q4 		$13.2M Sell
493,379
-1,865,502
-79% -$44.6M 0.01% 773
2025
Q3 		$50.3M Buy
2,358,881
+389,170
+20% +$9.2M 0.05% 314
2025
Q2 		$42.5M Buy
1,969,711
+1,639,315
+496% +$30.5M 0.05% 338
2025
Q1 		$5.49M Sell
330,396
-663,197
-67% -$12M 0.01% 1018
2024
Q4 		$18.2M Sell
993,593
-195,019
-16% -$3.15M 0.02% 578
2024
Q3 		$18.3M Sell
1,188,612
-1,585,741
-57% -$26.5M 0.02% 536
2024
Q2 		$45.1M Buy
2,774,353
+2,251,940
+431% +$36.3M 0.06% 285
2024
Q1 		$9.66M Buy
+522,413
New +$12.9M 0.01% 758
2023
Q4 		– Sell
-941,755
Closed -$19.6M – 2114
2023
Q3 		$19.6M Buy
941,755
+916,903
+3,689% +$24.9M 0.04% 446
2023
Q2 		$595K Buy
+24,852
New +$552K ﹤0.01% 1924
2022
Q2 		– Sell
-532,557
Closed -$12.9M – 3366
2022
Q1 		$12.9M Buy
+532,557
New +$12.9M 0.02% 704
2021
Q1 		– Sell
-848,679
Closed -$45.4M – 2412
2020
Q4 		$45.4M Sell
848,679
-285,133
-25% -$14.2M 0.25% 85
2020
Q3 		$46.8M Buy
1,133,812
+933,686
+467% +$40.3M 0.3% 73
2020
Q2 		$9.7M Buy
+200,126
New +$9.61M 0.07% 293
2016
Q2 		– Sell
-37,174
Closed -$1.04M – 965
2016
Q1 		$1.04M Buy
+37,174
New +$811K 0.01% 700
2015
Q2 		– Sell
-22,686
Closed -$739K – 879
2015
Q1 		$739K Buy
+22,686
New +$780K 0.01% 622

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace's ACAD Position: Q2 2026 in Review

Marshall Wace increased its Acadia Pharmaceuticals (ACAD) stake by 2,216% in Q2 2026, buying an estimated $37.2M and bringing the position to 1,764,838 shares worth $44.7M. The position accounts for 0.04% of the portfolio, ranked #418.

Marshall Wace first reported a position in ACAD in Q1 2015 and has held it in 18 quarters since. The position peaked at $50.3M in Q3 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Marshall Wace held 1,764,838 shares of Acadia Pharmaceuticals worth $44.7M as of Q2 2026.
  • Marshall Wace bought 1,688,651 Acadia Pharmaceuticals shares in Q2 2026, an estimated $37.2M.
  • Acadia Pharmaceuticals made up 0.04% of Marshall Wace's portfolio in Q2 2026, its #418 holding.
  • Marshall Wace first reported a position in Acadia Pharmaceuticals in Q1 2015 and has held it in 18 quarters since.
  • Marshall Wace's Acadia Pharmaceuticals position peaked at $50.3M in Q3 2025.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.